Cargando…
Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological processes including cancer. GSK-3 has two isoforms, GSK-3α and GSK-3β, and GSK-3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aim...
Autores principales: | Anraku, Tsutomu, Kuroki, Hiroo, Kazama, Akira, Bilim, Vladimir, Tasaki, Masaaki, Schmitt, Daniel, Mazar, Andrew, Giles, Francis J., Ugolkov, Andrey, Tomita, Yoshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984786/ https://www.ncbi.nlm.nih.gov/pubmed/31894292 http://dx.doi.org/10.3892/ijmm.2019.4427 |
Ejemplares similares
-
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
por: Kuroki, Hiroo, et al.
Publicado: (2019) -
Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2021) -
Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells
por: Shirono, Yuko, et al.
Publicado: (2023) -
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment
por: Kuroki, Hiroo, et al.
Publicado: (2021) -
Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2022)